Dr Vaishampayan on the Impact of TKI Combination Therapies i

Ulka Nitin Vaishampayan, MBBS, discusses updated data for frontline TKI combination therapies in the treatment of patients with metastatic renal cell carcinoma.

Related Keywords

Michigan , United States , Ulka Nitin Vaishampayan , Sunitinib Sutent , Phasei Program At Rogel Cancer Center , Database Consortium , University Of Michigan , International Metastatic , Phasei Program , Rogel Cancer Center , Science Summit ,